MR Imaging and Proton Spectroscopy of Neuronal Injury in Late-Onset G_M2 Gangliosidosis

References

1. ↵
   Navon R, Argov Z, Frisch A. Hexosaminidase A deficiency in adults. Am J Med Genet 1986;24:179–196

   CrossRefPubMedWeb of Science
2. ↵
   Walkley SU. Neurobiology and cellular pathogenesis of glycolipid storage diseases. Philos Trans R Soc Lond B Biol Sci 2003;358:893–904

   Abstract/FREE Full Text
3. ↵
   Navon R. Late-onset GM2 gangliosidosis and other hexosaminidase mutations among Jews. Adv Genet 2001;185–197
4. ↵
   Argov Z, Navon R. Clinical and genetic variations in the syndrome of adult GM2 gangliosidosis resulting from hexosaminidase A deficiency. Ann Neurol 1984;16:14–20

   CrossRefPubMedWeb of Science
5. ↵
   Brett EM, Ellis RB, Haas L, et al. Late onset GM2-gangliosidosis: clinical, pathological, and biochemical studies on 8 patients. Arch Dis Child 1973;48:775–785

   Abstract/FREE Full Text
6. ↵
   Zaroff CM, Neudorfer O, Morrison C, et al. Neuropsychological assessment of patients with late onset GM2 gangliosidosis. Neurology 2004;62:2283–2286

   Abstract/FREE Full Text
7. ↵
   Fukumizu M, Yoshikawa H, Takashima S, et al. Tay-Sachs disease: progression of changes on neuroimaging in four cases. Neuroradiology 1992;483–486
8. Streifler JY, Gornish M, Hadar H, Gadoth N. Brain imaging in late-onset GM2 gangliosidosis. Neurology 1993;43:2055–2058

   Abstract/FREE Full Text
9. ↵
   Mugikura S, Takahashi S, Higano S, et al. MR findings in Tay-Sachs disease. J Comput Assist Tomogr 1996;20:551–555

   CrossRefPubMed
10. ↵
    Suzuki K. Neuropathology of late onset gangliosidoses: a review. Dev Neurosci 1991;205–210
11. ↵
    Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001;265:54–84

    CrossRefPubMed
12. Tedeschi G, Schiffmann R, Barton NW, et al. Proton magnetic resonance spectroscopic imaging in childhood ataxia with diffuse central nervous system hypomyelination. Neurology 1995;45:1526–1532

    Abstract/FREE Full Text
13. Tedeschi G, Bonavita S, Barton NW, et al. Proton magnetic resonance spectroscopic imaging in the clinical evaluation of patients with Niemann-Pick type C disease. J Neurol Neurosurg Psychiatry 1998;65:72–79

    Abstract/FREE Full Text
14. ↵
    Tedeschi G, Bonavita S, Banerjee TK, et al. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 1999;52:1663–1667

    Abstract/FREE Full Text
15. ↵
    Tedeschi G, Bertolino A, Lundbom N, et al. Cortical and subcortical chemical pathology in Alzheimer’s disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 1996;47:696–704

    Abstract/FREE Full Text
16. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103–113

    Abstract/FREE Full Text
17. De Stefano N, Narayanan S, Matthews PM, et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999;122:1933–1939

    Abstract/FREE Full Text
18. ↵
    Inglese M, Li BS, Rusinek H, et al. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 2003;50:190–195

    CrossRefPubMedWeb of Science
19. Inglese M, Ge Y, Filippi M, et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825–1829

    CrossRefPubMedWeb of Science
20. ↵
    Patel SH, Inglese M, Glosser G, et al. Whole-brain n-acetylaspartate level and cognitive performance in HIV infection. AJNR Am J Neuroradiol 2003;24:1587–1591

    Abstract/FREE Full Text
21. ↵
    Miller BL. A review of chemical issues in 1H NMR spectroscopy: n-acetyl-l-aspartate, creatine and choline. NMR Biomed 1991;4:47–52

    PubMedWeb of Science
22. ↵
    Marion D, Ikura M, Bax A. Improved solvent suppression in one- and two-dimensional NMR spectra by convolution of time domain data. J Magn Reson 1989;84:425–430

    Web of Science
23. ↵
    Campbell ID, Dobson CM, Williams RJP, Xavier ZV. Resolution enhancement of protein PMR spectra using the difference between a broadened and normal spectrum. J Magn Reson 1973;11:172–181
24. ↵
    Gonen O, Murdoch JB, Stoyanova R, Goelman G. 3D multivoxel proton spectroscopy of human brain using a hybrid of 8th-order Hadamard encoding with 2D chemical shift imaging. Magn Reson Med 1998;39:34–40

    PubMed
25. ↵
    Soher BJ, Young K, Govindaraju V, Maudsley AA. Automated spectral analysis. III. Application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 1998;40:822–831

    PubMedWeb of Science
26. ↵
    Barker PB, Soher BJ, Blackband SJ, et al. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference. NMR Biomed 1993;6:89–94

    CrossRefPubMedWeb of Science
27. ↵
    Kreis R, Ernst T, Ross B. Absolute concentrations of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson 1993;102:9–19

    CrossRefWeb of Science
28. ↵
    Li BS, Babb JS, Soher BJ, et al. Reproducibility of 3D proton spectroscopy in the human brain. Magn Reson Med 2002;47:439–446

    CrossRefPubMed
29. ↵
    Suzuki K, Rapin I, Suzuki Y, Ishii N. Juvenile GM2-gangliosidosis: clinical variant of Tay-Sachs disease or a new disease. Neurology 1970;20:190–204

    FREE Full Text
30. Menkes JH, O’Brien JS, Okada S, et al. Juvenile GM2 gangliosidosis: biochemical and ultrastructural studies on a new variant of Tay-Sachs disease. Arch Neurol 1971;25:14–22

    CrossRefPubMedWeb of Science
31. Buxton P, Cumings JN, Ellis RB, et al. A case of GM2 gangliosidosis of late onset. J Neurol Neurosurg Psychiatry 1972;35:685–692

    Abstract/FREE Full Text
32. ↵
    Rapin I, Suzuki K, Valsamis MP. Adult (chronic) GM2 gangliosidosis: atypical spinocerebellar degeneration in a Jewish sibship. Arch Neurol 1976;33:120–130

    CrossRefPubMedWeb of Science
33. ↵
    Jeyakumar M, Butters TD, Dwek RA, Platt FM. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol 2002;28:343–357

    CrossRefPubMedWeb of Science
34. ↵
    Brenner RE, Munro PM, Williams SC, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho: Cr ratio. Magn Reson Med 1993;29:737–745

    PubMedWeb of Science
35. ↵
    De Stefano N, Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901–909

    CrossRefPubMedWeb of Science
36. ↵
    Felderhoff-Mueser U, Sperner J, Konstanzcak P, et al. 31Phosphorus magnetic resonance spectroscopy in late-onset Tay-Sachs disease. J Child Neurol 2001;16:377–380

    Abstract/FREE Full Text
37. ↵
    Walkley SU. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 2004;15:433–444

    CrossRefPubMedWeb of Science
38. ↵
    Coetzee T, Suzuki K, Popko B. New perspectives on the function of myelin galactolipids. Trends Neurosci 1998;21:126–130

    CrossRefPubMedWeb of Science
39. ↵
    Platt FM, Neises GR, Reinkensmeier G, et al. Prevention of lysosomal storage in Tay-Sachs mice treated with n-butyldeoxynojirimycin. Science 1997;276:428–431

    Abstract/FREE Full Text
40. ↵
    Butters TD, Dwek RA, Platt FM. Therapeutic applications of imino sugars in lysosomal storage disorders. Adv Exp Med Biol 2003;561–574